Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 versus standard of care in pediatric Wilson disease
2021-001015-82Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Wilson disease (WD) comparing ALXN1840 with Standard of care (2 arms). Primary endpoint: Percentage change from baseline to Week 48 in plasma NCC. Started Aug 2021; status: terminated.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2021-001015-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001015-82.